![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Safety, Efficacy, and Pharmacokinetics of the Integrase Inhibitor-Based E/C/F/TAF Single-Tablet Regimen in Treatment-Naïve HIV-Infected Adolescents Through 24 Weeks of Treatment
|
|
|
Reported by Jules Levin
16th International Workshop on Clinical Pharmacology of HIV & Hepatitis Therapy, May 26-28, 2015, Washington, DC, USA
Hilda Kizito,1 Aditya Gaur,2 Wasana Prasitsuebsai,3 Natella Rakhmanina,4 Eileen Lawson,5 Yongwu Shao,5 Sean Bennett,5 Andrew Cheng,5 Erin Quirk5
1Joint Clinical Research Centre, Kampala, Uganda; 2St Jude Children's Research Hospital, Memphis, Tennessee, USA; 3The HIV Netherlands Australia Thailand
Research Collaboration, Bangkok, Thailand; 4Children's National Health System, Washington, DC, USA; 5Gilead Sciences, Inc., Foster City, California, USA
CROI: Safety, Efficacy and Pharmacokinetics of the Integrase Inhibitor-Based E/C/F/TAF Single-Tablet Regimen in Treatment-Naïve HIV-Infected Adolescents Through 24 Weeks of Treatment - (03/16/15)
![pharm1.gif](../images/060215/060215-5/pharm1.gif)
![pharm2.gif](../images/060215/060215-5/pharm2.gif)
![pharm3.gif](../images/060215/060215-5/pharm3.gif)
![pharm4.gif](../images/060215/060215-5/pharm4.gif)
![pharm5.gif](../images/060215/060215-5/pharm5.gif)
![pharm6.gif](../images/060215/060215-5/pharm6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|